{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:54:27Z","timestamp":1792000467685,"version":"4.4.0"},"reference-count":61,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Human papillomavirus (HPV) vaccination is widely reported as cost-effective, but reported incremental cost-effectiveness ratios (ICERs) are shaped by model structure, assumptions, comparator choice, vaccine price, threshold selection, and local screening context. Previous reviews have summarized cost-effectiveness findings but have less often examined why conclusions differ across settings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To map methodological evolution, drivers of variation, reporting completeness, methodological credibility, and transferability in HPV vaccination economic evaluations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A scoping review was conducted using the methodological framework proposed by Arksey and O\u2019Malley, refined by Levac et al., and informed by JBI guidance for scoping reviews. Reporting followed PRISMA-ScR, and the protocol was preregistered on the Open Science Framework (OSF). PubMed, Scopus, PsycINFO, Embase, Web of Science, and CINAHL were searched from January 1, 2003, to December 31, 2025, with a final search conducted on January 2, 2026. Forty-four records were mapped. Thirty-three full comparative economic evaluations formed the primary synthesis; 11 partial or non-standard economic evidence records were retained as contextual evidence. The Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) checklist was applied retrospectively to assess reporting completeness, and a descriptive structured appraisal was used to examine methodological credibility across six health-economic domains. A Welte-informed assessment was used to examine target-context contextualization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The evidence base evolved from early static cohort models to dynamic transmission and individual-based approaches, while static models remained common in LMIC-focused standardized-tool analyses. The main drivers of variation were vaccine price, discounting, herd-immunity assumptions, cross-protection assumptions, and threshold selection. Reporting completeness varied and did not necessarily correspond to methodological credibility. Relevance to a study\u2019s own decision setting did not imply that its ICER could be transferred to other countries. Eleven contextual records showed emerging policy questions around delivery costs, fiscal consequences, uptake, risk-benefit framing, and non-ICER-based decision support.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec005\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The economic value reported for HPV vaccination depends on the assumptions, comparators, vaccine prices, thresholds, and local screening contexts used in each evaluation rather than on the vaccine alone. Future evaluations should explicitly justify the choice of comparator, model structure, vaccine-price assumptions, discount rates, thresholds, uncertainty analysis, and transferability assumptions. Although formal cost-effectiveness analyses of single-dose HPV vaccination have begun to emerge, evidence remains limited, particularly regarding durability, waning, delivery feasibility, gender-neutral vaccination in LMICs, and country-specific evaluations in underrepresented regions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0360732","type":"journal-article","created":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:26:58Z","timestamp":1791998818000},"page":"e0360732","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Methodological drivers, reporting completeness, and transferability in HPV vaccination economic evaluations: A scoping review"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7825-3436","authenticated-orcid":true,"given":"Adnan","family":"Kisa","sequence":"first","affiliation":[{"name":"Kristiania University of Applied Sciences","place":["Oslo, Norway"],"department":["School of Health Sciences"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sezer","family":"Kisa","sequence":"additional","affiliation":[{"name":"Oslo Metropolitan University","place":["Oslo, Norway"],"department":["Department of Nursing and Health Promotion, Faculty of Health Sciences"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,10,14]]},"reference":[{"key":"pone.0360732.ref001","unstructured":"Organization WH. Global strategy to accelerate the elimination of cervical cancer as a public health problem. 2020. [cited 2026 May 8]. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789240014107"},{"issue":"3","key":"pone.0360732.ref002","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"H Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"pone.0360732.ref003","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1093\/jnci\/djh104","article-title":"Projected clinical benefits and cost-effectiveness of a human papillomavirus 16\/18 vaccine","volume":"96","author":"SJ Goldie","year":"2004","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"pone.0360732.ref004","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0233499","article-title":"Cost-effectiveness evaluations of the 9-Valent human papillomavirus (HPV) vaccine: Evidence from a systematic review","volume":"15","author":"RA Mahumud","year":"2020","journal-title":"PLoS One"},{"issue":"19","key":"pone.0360732.ref005","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1016\/j.vaccine.2018.03.024","article-title":"Systematic review of cost-effectiveness studies of human papillomavirus (HPV) vaccination: 9-Valent vaccine, gender-neutral and multiple age cohort vaccination","volume":"36","author":"SS Ng","year":"2018","journal-title":"Vaccine"},{"issue":"1","key":"pone.0360732.ref006","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3201\/eid1301.060438","article-title":"Model for assessing human papillomavirus vaccination strategies","volume":"13","author":"EH Elbasha","year":"2007","journal-title":"Emerg Infect Dis"},{"issue":"26","key":"pone.0360732.ref007","doi-asserted-by":"crossref","first-page":"3237","DOI":"10.1016\/j.vaccine.2014.03.098","article-title":"Two-dose strategies for human papillomavirus vaccination: How well do they need to protect?","volume":"32","author":"M Jit","year":"2014","journal-title":"Vaccine"},{"issue":"50","key":"pone.0360732.ref008","first-page":"645","article-title":"Human papillomavirus vaccines: WHO position paper (2022 update)","volume":"97","author":"WH Organization","year":"2022","journal-title":"Wkly Epidemiol Rec"},{"issue":"8","key":"pone.0360732.ref009","article-title":"Summaries for patients. Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in women older than 30 years in the United States","volume":"151","author":"JJ Kim","year":"2009","journal-title":"Ann Intern Med"},{"issue":"1","key":"pone.0360732.ref010","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1186\/s12879-019-4108-y","article-title":"Assessing the cost-effectiveness of HPV vaccination strategies for adolescent girls and boys in the UK","volume":"19","author":"S Datta","year":"2019","journal-title":"BMC Infect Dis"},{"issue":"1","key":"pone.0360732.ref011","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1080\/13696998.2023.2282912","article-title":"Health impact and cost effectiveness of implementing gender-neutral HPV vaccination in Japan","volume":"26","author":"C Palmer","year":"2023","journal-title":"J Med Econ"},{"issue":"13","key":"pone.0360732.ref012","doi-asserted-by":"crossref","first-page":"857","DOI":"10.2165\/00019053-200422130-00004","article-title":"A decision chart for assessing and improving the transferability of economic evaluation results between countries","volume":"22","author":"R Welte","year":"2004","journal-title":"Pharmacoeconomics"},{"issue":"8","key":"pone.0360732.ref013","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0309597","article-title":"Religious beliefs and practices toward HPV vaccine acceptance in Islamic countries: A scoping review","volume":"19","author":"S Kisa","year":"2024","journal-title":"PLoS One"},{"issue":"6","key":"pone.0360732.ref014","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s40273-021-01112-8","article-title":"Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations","volume":"40","author":"D Husereau","year":"2022","journal-title":"Pharmacoeconomics"},{"issue":"8","key":"pone.0360732.ref015","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1177\/09564624231165547","article-title":"A targeted literature review of health economic analyses of human papillomavirus vaccination from various countries","volume":"34","author":"HA Segal","year":"2023","journal-title":"Int J STD AIDS"},{"key":"pone.0360732.ref016","article-title":"Projected cost-effectiveness of new vaccines for adolescents in the United States","volume":"121","author":"IR Ortega-Sanchez","year":"2008","journal-title":"Pediatrics"},{"issue":"1","key":"pone.0360732.ref017","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/1364557032000119616","article-title":"Scoping studies: Towards a methodological framework","volume":"8","author":"H Arksey","year":"2005","journal-title":"Int J Soc Res Methodol"},{"key":"pone.0360732.ref018","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1748-5908-5-69","article-title":"Scoping studies: Advancing the methodology","volume":"5","author":"D Levac","year":"2010","journal-title":"Implement Sci"},{"key":"pone.0360732.ref019","doi-asserted-by":"crossref","unstructured":"Peters M, et al. Chapter 11: Scoping Reviews. 2020.","DOI":"10.46658\/JBIRM-20-01"},{"issue":"7","key":"pone.0360732.ref020","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation","volume":"169","author":"AC Tricco","year":"2018","journal-title":"Ann Intern Med"},{"issue":"9","key":"pone.0360732.ref021","doi-asserted-by":"crossref","first-page":"781","DOI":"10.2165\/11586560-000000000-00000","article-title":"Economic evaluation of policy options for prevention and control of cervical cancer in Thailand","volume":"29","author":"N Praditsitthikorn","year":"2011","journal-title":"Pharmacoeconomics"},{"issue":"11","key":"pone.0360732.ref022","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0080639","article-title":"Cost-effectiveness analysis of the bivalent and quadrivalent human papillomavirus vaccines from a societal perspective in Colombia","volume":"8","author":"J Aponte-Gonz\u00e1lez","year":"2013","journal-title":"PLoS One"},{"key":"pone.0360732.ref023","article-title":"Model-based impact and cost-effectiveness of cervical cancer prevention in Sub-Saharan Africa","volume":"31","author":"JJ Kim","year":"2013","journal-title":"Vaccine"},{"key":"pone.0360732.ref024","article-title":"Model-based impact and cost-effectiveness of cervical cancer prevention in the Extended Middle East and North Africa (EMENA)","author":"JJ Kim","year":"2013","journal-title":"Vaccine"},{"issue":"1","key":"pone.0360732.ref025","doi-asserted-by":"crossref","first-page":"140","DOI":"10.36469\/jheor.2022.34721","article-title":"Assessing the health and economic outcomes of a 9-Valent HPV vaccination program in the United Kingdom","volume":"9","author":"K Owusu-Edusei","year":"2022","journal-title":"J Health Econ Outcomes Res"},{"issue":"1","key":"pone.0360732.ref026","doi-asserted-by":"crossref","first-page":"3561","DOI":"10.1186\/s12889-025-24878-4","article-title":"Cost effectiveness of female HPV vaccines for routine childhood immunisation schedule in T\u00fcrkiye","volume":"25","author":"\u00c7E \u015eahin","year":"2025","journal-title":"BMC Public Health"},{"issue":"1","key":"pone.0360732.ref027","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/2191-1991-2-19","article-title":"Cost-effectiveness of vaccination with a quadrivalent HPV vaccine in Germany using a dynamic transmission model","volume":"2","author":"D Schobert","year":"2012","journal-title":"Health Econ Rev"},{"issue":"29","key":"pone.0360732.ref028","doi-asserted-by":"crossref","first-page":"4362","DOI":"10.1016\/j.vaccine.2018.04.071","article-title":"Cost-effectiveness of nonavalent HPV vaccination among males aged 22 through 26 years in the United States","volume":"36","author":"HW Chesson","year":"2018","journal-title":"Vaccine"},{"issue":"2","key":"pone.0360732.ref029","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3111\/13696998.2010.490481","article-title":"Modelling the economic value of cross- and sustained-protection in vaccines against cervical cancer","volume":"13","author":"N Demarteau","year":"2010","journal-title":"J Med Econ"},{"issue":"2","key":"pone.0360732.ref030","doi-asserted-by":"crossref","first-page":"425","DOI":"10.31557\/APJCP.2019.20.2.425","article-title":"Cost-utility of a two-dose human papillomavirus vaccination programme added to cervical cancer screening compared with cervical cancer screening alone in Korea","volume":"20","author":"H Lee","year":"2019","journal-title":"Asian Pac J Cancer Prev"},{"issue":"5","key":"pone.0360732.ref031","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.31557\/APJCP.2019.20.5.1377","article-title":"Cost-effectiveness analysis of human papillomavirus vaccination in adolescent girls in Taiwan","volume":"20","author":"C-H Tang","year":"2019","journal-title":"Asian Pac J Cancer Prev"},{"key":"pone.0360732.ref032","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.vhri.2018.03.001","article-title":"Cost-effectiveness analysis of the introduction of hpv vaccination of 9-year-old-girls in Iran","volume":"15","author":"M Yaghoubi","year":"2018","journal-title":"Value Health Reg Issues"},{"key":"pone.0360732.ref033","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.vhri.2015.12.002","article-title":"Cost-effectiveness study of HPV vaccination as a primary prevention strategy for anal cancer in HIV-positive men in Chile","volume":"11","author":"C Vargas Parada","year":"2016","journal-title":"Value Health Reg Issues"},{"issue":"33","key":"pone.0360732.ref034","doi-asserted-by":"crossref","first-page":"6245","DOI":"10.1016\/j.vaccine.2007.05.061","article-title":"Assessing the introduction of universal human papillomavirus vaccination for preadolescent girls in The Netherlands","volume":"25","author":"HJ Boot","year":"2007","journal-title":"Vaccine"},{"key":"pone.0360732.ref035","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1478-7547-6-4","article-title":"Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: A cost-effectiveness analysis","volume":"6","author":"SL Kulasingam","year":"2008","journal-title":"Cost Eff Resour Alloc"},{"issue":"4","key":"pone.0360732.ref036","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/ijc.24000","article-title":"HPV 16\/18 vaccination to prevent cervical cancer in the Netherlands: Model-based cost-effectiveness","volume":"124","author":"VMH Coup\u00e9","year":"2009","journal-title":"Int J Cancer"},{"issue":"6","key":"pone.0360732.ref037","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.arcmed.2009.08.004","article-title":"Cost-effectiveness analysis of a quadrivalent human papilloma virus vaccine in Mexico","volume":"40","author":"LM Reynales-Shigematsu","year":"2009","journal-title":"Arch Med Res"},{"issue":"1","key":"pone.0360732.ref038","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3111\/13696990903546013","article-title":"The cost effectiveness of a quadrivalent human papillomavirus vaccine (6\/11\/16\/18) in Hungary","volume":"13","author":"EJ Dasbach","year":"2010","journal-title":"J Med Econ"},{"key":"pone.0360732.ref039","doi-asserted-by":"crossref","DOI":"10.1016\/j.jval.2011.11.007","article-title":"Cost and effectiveness evaluation of prophylactic HPV vaccine in developing countries","volume":"15","author":"W Termrungruanglert","year":"2012","journal-title":"Value Health"},{"key":"pone.0360732.ref040","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2013.04.086","article-title":"Cost-effectiveness of cervical cancer prevention in central and Eastern Europe and Central Asia","volume":"31","author":"J Berkhof","year":"2013","journal-title":"Vaccine"},{"issue":"1","key":"pone.0360732.ref041","doi-asserted-by":"crossref","DOI":"10.1186\/s12889-016-2754-1","article-title":"Cost- effectiveness of HPV vaccination regime: Comparing twice versus thrice vaccinations dose regime among adolescent girls in Malaysia health policies, systems and management in high-income countries","volume":"16","author":"S Aljunid","year":"2016","journal-title":"BMC Public Health"},{"key":"pone.0360732.ref042","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.vhri.2015.10.010","article-title":"Cost-utility analysis of human papillomavirus vaccination and cervical screening on cervical cancer patient in Indonesia","volume":"9","author":"D Setiawan","year":"2016","journal-title":"Value Health Reg Issues"},{"issue":"7","key":"pone.0360732.ref043","first-page":"2011","article-title":"The cost-effectiveness of quadrivalent human papillomavirus vaccination in Indonesia","volume":"18","author":"S Kosen","year":"2017","journal-title":"Asian Pacific J Cancer Prev"},{"key":"pone.0360732.ref044","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12962-017-0073-8","article-title":"Cost-effectiveness analysis of the nine-valent HPV vaccine in Italy","volume":"15","author":"FS Mennini","year":"2017","journal-title":"Cost Eff Resour Alloc"},{"issue":"11","key":"pone.0360732.ref045","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1080\/13696998.2019.1624556","article-title":"Cervical cancer prevention in Morocco: a model-based cost-effectiveness analysis","volume":"22","author":"W Messoudi","year":"2019","journal-title":"J Med Econ"},{"issue":"9","key":"pone.0360732.ref046","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0238291","article-title":"Cost effectiveness of strategies for cervical cancer prevention in India","volume":"15","author":"AS Chauhan","year":"2020","journal-title":"PLoS One"},{"key":"pone.0360732.ref047","doi-asserted-by":"crossref","first-page":"100675","DOI":"10.1016\/j.jcpo.2025.100675","article-title":"Economic evaluation of the one-dose HPV vaccination program in Nigeria","volume":"47","author":"T Gao","year":"2026","journal-title":"J Cancer Policy"},{"issue":"3","key":"pone.0360732.ref048","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.ygyno.2011.01.029","article-title":"Cost-consequences evaluation between bivalent and quadrivalent HPV vaccines in Italy: the potential impact of different cross-protection profiles","volume":"121","author":"S Capri","year":"2011","journal-title":"Gynecol Oncol"},{"key":"pone.0360732.ref049","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-015-1067-9","article-title":"Vaccination of boys or catch-up of girls above 11 years of age with the HPV-16\/18 AS04-adjuvanted vaccine: Where is the greatest benefit for cervical cancer prevention in Italy?","volume":"15","author":"P Bonanni","year":"2015","journal-title":"BMC Infect Dis"},{"issue":"4","key":"pone.0360732.ref050","doi-asserted-by":"crossref","first-page":"823","DOI":"10.4161\/hv.22994","article-title":"A comparative analysis of the epidemiological impact and disease cost-savings of HPV vaccines in France","volume":"9","author":"X Bresse","year":"2013","journal-title":"Hum Vaccin Immunother"},{"issue":"67","key":"pone.0360732.ref051","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/jncimonographs\/lgae037","article-title":"Evaluating potential program cost savings with a single-dose HPV vaccination schedule: A modeling study","volume":"2024","author":"R Slavkovsky","year":"2024","journal-title":"J Natl Cancer Inst Monogr"},{"issue":"6","key":"pone.0360732.ref052","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1007\/s10935-022-00697-w","article-title":"Cost-benefit analysis of human papillomavirus vaccine in Iran","volume":"43","author":"N Sargazi","year":"2022","journal-title":"J Prev (2022)"},{"issue":"10","key":"pone.0360732.ref053","doi-asserted-by":"crossref","first-page":"715","DOI":"10.26719\/2019.25.10.715","article-title":"Cost-benefit analysis of a projected national human papilloma virus vaccination programme in Lebanon","volume":"25","author":"S Bahr","year":"2019","journal-title":"East Mediterr Health J"},{"issue":"8","key":"pone.0360732.ref054","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0160707","article-title":"Assessment of the broader economic consequences of HPV prevention from a government-perspective: A fiscal analytic approach","volume":"11","author":"D Setiawan","year":"2016","journal-title":"PLoS One"},{"issue":"2","key":"pone.0360732.ref055","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3747\/co.26.4795","article-title":"Moving toward the elimination of cervical cancer: modelling the health and economic benefits of increasing uptake of human papillomavirus vaccines","volume":"26","author":"A Smith","year":"2019","journal-title":"Curr Oncol"},{"issue":"2","key":"pone.0360732.ref056","doi-asserted-by":"crossref","first-page":"114","DOI":"10.7883\/yoken.JJID.2021.367","article-title":"Risk-benefit analysis of the 9-valent HPV vaccination for adolescent boys from an individual perspective","volume":"75","author":"T Kitano","year":"2022","journal-title":"Jpn J Infect Dis"},{"issue":"6","key":"pone.0360732.ref057","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2024.35.e85","article-title":"Cost-effectiveness analysis of single-dose or 2-dose of bivalent, quadrivalent, or nonavalent HPV vaccine in a low\/middle-income country setting","volume":"35","author":"W Termrungruanglert","year":"2024","journal-title":"J Gynecol Oncol"},{"issue":"7543","key":"pone.0360732.ref058","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1136\/bmj.38737.607558.80","article-title":"Bias in published cost effectiveness studies: Systematic review","volume":"332","author":"CM Bell","year":"2006","journal-title":"BMJ"},{"issue":"15","key":"pone.0360732.ref059","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1001\/jama.282.15.1453","article-title":"Evaluation of conflict of interest in economic analyses of new drugs used in oncology","volume":"282","author":"M Friedberg","year":"1999","journal-title":"JAMA"},{"issue":"3","key":"pone.0360732.ref060","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/sj.bjc.6603575","article-title":"Strategies for the introduction of human papillomavirus vaccination: Modelling the optimum age- and sex-specific pattern of vaccination in Finland","volume":"96","author":"KM French","year":"2007","journal-title":"Br J Cancer"},{"key":"pone.0360732.ref061","doi-asserted-by":"crossref","first-page":"100184","DOI":"10.1016\/j.pvr.2019.100184","article-title":"HPV-FRAME: A consensus statement and quality framework for modelled evaluations of HPV-related cancer control","volume":"8","author":"K Canfell","year":"2019","journal-title":"Papillomavirus Res"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0360732","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:27:07Z","timestamp":1791998827000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0360732"}},"subtitle":[],"editor":[{"given":"Cecilia","family":"Acuti Martellucci","sequence":"first","affiliation":[{"name":"University of Bologna: Universita di Bologna","place":["ITALY"]}],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,10,14]]},"references-count":61,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10,14]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0360732","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,14]]}}}